[go: up one dir, main page]

HN1999000075A - Agonistas y antagonistas il-2 selectivos - Google Patents

Agonistas y antagonistas il-2 selectivos

Info

Publication number
HN1999000075A
HN1999000075A HN1999000075A HN1999000075A HN1999000075A HN 1999000075 A HN1999000075 A HN 1999000075A HN 1999000075 A HN1999000075 A HN 1999000075A HN 1999000075 A HN1999000075 A HN 1999000075A HN 1999000075 A HN1999000075 A HN 1999000075A
Authority
HN
Honduras
Prior art keywords
selective
agonists
antagonists
present
natural killer
Prior art date
Application number
HN1999000075A
Other languages
English (en)
Inventor
Bayer Corporation
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of HN1999000075A publication Critical patent/HN1999000075A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE EN TERMINOS GENERALES A LOS CAMPOS DE LA FARMACOLOGIA E INMUNOLOGIA. MAS ESPECIFICAMENTE, A NOVEDOSAS COMPOSICIONES DE MATERIAL PARA LA ACTIVACION SELECTIVA DE CELULAS T (PHABLASTOS), Y QUE PRESENTAN UNA ACTIVACION REDUCIDA DE LAS CELULAS ASESINAS NATURALES (NK, NATURAL KILLER CELLS).LAS NOVEDOSAS COMPOSICIONES INCLUYEN VARIANTES DE LA FAMILIA DE LAS CITOQUINAS Y EN PARTICULAR LA INTERLEUQUINA-2 HUMANA ("IL-2 SELECTIVOS.
HN1999000075A 1998-05-15 1999-05-14 Agonistas y antagonistas il-2 selectivos HN1999000075A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8008098A 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
HN1999000075A true HN1999000075A (es) 1999-09-29

Family

ID=22155135

Family Applications (1)

Application Number Title Priority Date Filing Date
HN1999000075A HN1999000075A (es) 1998-05-15 1999-05-14 Agonistas y antagonistas il-2 selectivos

Country Status (39)

Country Link
EP (1) EP1076704B1 (es)
JP (1) JP4276783B2 (es)
KR (1) KR100607609B1 (es)
CN (2) CN101319247B (es)
AR (1) AR020322A1 (es)
AT (1) ATE351907T1 (es)
AU (1) AU759697B2 (es)
BG (1) BG65139B1 (es)
BR (1) BRPI9910504B1 (es)
CA (1) CA2327349C (es)
CO (1) CO5070701A1 (es)
CU (2) CU23273B7 (es)
CY (1) CY1107533T1 (es)
CZ (1) CZ302071B6 (es)
DE (1) DE69934881T2 (es)
DK (1) DK1076704T3 (es)
DZ (1) DZ2788A1 (es)
ES (1) ES2281175T3 (es)
HK (1) HK1039963B (es)
HN (1) HN1999000075A (es)
HU (1) HU226142B1 (es)
IL (2) IL139136A0 (es)
MY (1) MY130274A (es)
NO (1) NO329235B1 (es)
NZ (1) NZ508098A (es)
PA (1) PA8472601A1 (es)
PE (1) PE20000475A1 (es)
PL (1) PL201675B1 (es)
PT (1) PT1076704E (es)
RO (1) RO122150B1 (es)
RU (1) RU2235729C2 (es)
SI (1) SI20643B (es)
SK (1) SK288100B6 (es)
SV (1) SV1999000061A (es)
TN (1) TNSN99090A1 (es)
TR (1) TR200003354T2 (es)
TW (1) TWI223663B (es)
UA (1) UA73719C2 (es)
WO (1) WO1999060128A1 (es)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029732A2 (en) 1997-12-08 1999-06-17 Lexigen Pharmaceuticals Corporation Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
AU4057300A (en) 1999-03-30 2000-10-16 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinacious compounds
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
WO2001058957A2 (en) 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
EP1935431A3 (en) 2000-05-15 2008-08-13 Health Research, Inc. Cancer treatments by using a combination of an antibody against her2 and interleukin-2
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
US7517526B2 (en) 2000-06-29 2009-04-14 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US7723102B2 (en) * 2000-09-28 2010-05-25 Bayer Corporation Enhanced transfection system
MY139948A (en) * 2000-09-28 2009-11-30 Bayer Corp Enhanced transfection system
EP1366067B1 (en) 2001-03-07 2012-09-26 Merck Patent GmbH Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
DE60239454D1 (de) 2001-05-03 2011-04-28 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
ATE542137T1 (de) * 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
BRPI0317376B8 (pt) 2002-12-17 2021-05-25 Merck Patent Gmbh proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
EP1944318B1 (en) 2003-07-21 2011-03-02 Transgene S.A. Multifunctional cytokines
EP2149585B1 (en) 2003-11-04 2013-08-14 Novartis Vaccines and Diagnostics, Inc. Use of antagonistic anti-CD40 monoclonal antibodies
ATE516305T1 (de) * 2004-02-27 2011-07-15 Inst Nat Sante Rech Med Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten
CA2557677A1 (en) * 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
CN101244261B (zh) * 2008-03-10 2010-09-15 山东大学 一种含未复性重组蛋白的生物制剂及其制备方法与应用
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
US20110274650A1 (en) 2009-01-21 2011-11-10 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
CN102101885B (zh) * 2010-09-01 2013-06-05 南京发士达生物科技有限公司 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
MX388465B (es) 2010-11-12 2025-03-20 Nektar Therapeutics Conjugados de un resto de interleucina-2 y un polímero.
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
JP6093712B2 (ja) * 2010-12-22 2017-03-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン２のスーパーアゴニストおよびアンタゴニスト
PL3489255T3 (pl) 2011-02-10 2021-11-22 Roche Glycart Ag Zmutowane polipeptydy interleukiny-2
WO2012119093A1 (en) * 2011-03-03 2012-09-07 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
WO2015042707A1 (en) 2013-09-24 2015-04-02 Medicenna Therapeutics Pte Ltd Interleukin-2 fusion proteins and uses thereof
NZ719654A (en) 2014-02-06 2020-06-26 Hoffmann La Roche Interleukin-2 fusion proteins and uses thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10150802B2 (en) 2014-04-24 2018-12-11 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
CN113234138A (zh) * 2014-08-11 2021-08-10 德里尼亚公司 选择性地活化调节性t细胞用于治疗自身免疫病的修饰的il-2变体
WO2017062832A1 (en) 2015-10-08 2017-04-13 Nektar Therapeutics Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
KR20240115933A (ko) * 2016-05-04 2024-07-26 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
US12202856B2 (en) 2016-05-19 2025-01-21 The General Hospital Corporation Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
JP7206190B2 (ja) * 2016-06-22 2023-01-17 ダヴィド・クラッツマン 遺伝的に修飾されたｔリンパ球
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
MX2019005400A (es) 2016-11-08 2019-08-05 Delinia Inc Variantes de il-2 para el tratamiento de enfermedades autoinmunes.
CA3044416A1 (en) * 2016-12-13 2018-06-21 Delinia, Inc. Multivalent regulatory t cell modulators
US10961310B2 (en) 2017-03-15 2021-03-30 Pandion Operations, Inc. Targeted immunotolerance
CN111107868A (zh) * 2017-05-24 2020-05-05 诺华股份有限公司 抗体细胞因子移植蛋白及使用方法
EA201992765A1 (ru) 2017-05-24 2020-03-25 Новартис Аг Белки на основе антител с привитым цитокином и способы их применения в лечении рака
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
SG11201909949XA (en) 2017-05-24 2019-11-28 Pandion Therapeutics Inc Targeted immunotolerance
US11542312B2 (en) 2017-06-19 2023-01-03 Medicenna Therapeutics, Inc. IL-2 superagonists in combination with anti-PD-1 antibodies
KR20250130723A (ko) * 2017-08-03 2025-09-02 신톡스, 인크. 증식성 질환 및 감염성 질환의 치료를 위한 사이토카인 접합체
MX2020005041A (es) * 2017-11-21 2020-10-12 Univ Leland Stanford Junior Agonistas parciales de interleucina-2.
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
US11534479B2 (en) 2018-02-16 2022-12-27 Iltoo Pharma Use of interleukin 2 for treating Sjögren's syndrome
MX2020009975A (es) 2018-03-28 2020-10-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso.
EP3773680A1 (en) 2018-03-28 2021-02-17 Ascendis Pharma Oncology Division A/S Il-2 conjugates
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
WO2020020783A1 (en) * 2018-07-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Il2 agonists
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
CN111971295B (zh) 2018-09-17 2024-08-02 Gi医诺微新 包含il-2蛋白和cd80蛋白的融合蛋白及其用途
AU2019343251B2 (en) 2018-09-21 2022-06-09 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin 2 and use thereof
CN113383013B (zh) 2018-12-21 2022-11-04 江苏恒瑞医药股份有限公司 一种人白细胞介素2变体或其衍生物
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
TW202115105A (zh) * 2019-06-24 2021-04-16 德商拜恩迪克Ｒｎａ製藥有限公司 Ｉｌ２激動劑
US12084484B2 (en) 2019-07-26 2024-09-10 Visterra, Inc. Interleukin-2 agents and uses thereof
MX2022001866A (es) * 2019-08-13 2022-03-11 Amgen Inc Muteinas de interleucina-2 para la expansion de celulas t reguladoras.
EP4073094A1 (en) 2019-12-12 2022-10-19 Iltoo Pharma Interleukin 2 chimeric constructs
WO2021127262A1 (en) 2019-12-17 2021-06-24 Amgen Inc. Dual interleukin-2 /tnf receptor agonist for use in therapy
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
EP4090354A4 (en) * 2020-01-14 2024-05-22 Synthekine, Inc. IL2 MUTEINS
MX2022008771A (es) 2020-01-14 2022-10-07 Synthekine Inc Metodos y composiciones de muteinas de il2 sesgadas.
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
JP2023518434A (ja) 2020-03-19 2023-05-01 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド インターロイキン２変異体およびその使用
CN115427437B (zh) 2020-03-31 2024-04-19 韩美药品株式会社 新型免疫刺激il-2类似物
TW202210502A (zh) 2020-06-03 2022-03-16 丹麥商阿森迪斯腫瘤製藥有限公司 新穎il-2序列及其用途
CN114507643A (zh) * 2020-10-29 2022-05-17 未来智人再生医学研究院(广州)有限公司 一种表达il-2的多能干细胞衍生物及应用
KR20230097094A (ko) 2020-10-29 2023-06-30 브리스톨-마이어스 스큅 컴퍼니 질환의 치료를 위한 융합 단백질
EP4255466A1 (en) 2020-12-04 2023-10-11 Visterra, Inc. Methods of using interleukin-2 agents
CN113308477A (zh) * 2021-04-08 2021-08-27 华南农业大学 一种鸭il-2基因真核表达重组质粒及其制备方法
US20240391973A1 (en) 2021-09-22 2024-11-28 Fortvita Biologics (Singapore) Pte. Ltd. Interleukin-2 mutant and fusion protein thereof
CN118414160A (zh) 2021-10-06 2024-07-30 艾尔图制药公司 对发炎组织具有靶向特异性的白介素2嵌合构建体
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
CN119731204A (zh) * 2022-06-16 2025-03-28 赛福伦有限责任公司 抗pd-1抗体-衰减的il-2免疫偶联物及其用途
CA3265946A1 (en) 2022-09-12 2024-03-21 Sorbonne Universite INTERLEUKIN-2 FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS
FR3140287B1 (fr) 2022-10-03 2025-11-21 Arkema France Procede de granulation de composes azoiques et granules obtenus
AU2023382265A1 (en) 2022-11-18 2025-10-09 Nanjing Novoacine Biotechnology Co., Ltd. Site-specific coupled pegylated interleukin-2 mutant with receptor affinity preference and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2003334C1 (ru) * 1988-07-26 1993-11-30 Хем Рисерч, Инк, (US) Способ лечени больных с опухол ми
FR2684878B1 (fr) * 1991-12-12 1994-02-11 Roussel Uclaf Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13

Also Published As

Publication number Publication date
CA2327349C (en) 2010-10-26
EP1076704B1 (en) 2007-01-17
TWI223663B (en) 2004-11-11
CA2327349A1 (en) 1999-11-25
KR20010043602A (ko) 2001-05-25
SI20643B (sl) 2008-02-29
RU2235729C2 (ru) 2004-09-10
AU759697B2 (en) 2003-04-17
CU23273B7 (es) 2008-04-09
BG104929A (en) 2001-09-28
CZ20004213A3 (en) 2001-05-16
ES2281175T3 (es) 2007-09-16
SI20643A (sl) 2002-02-28
JP4276783B2 (ja) 2009-06-10
NO329235B1 (no) 2010-09-20
HUP0101948A3 (en) 2003-08-28
RO122150B1 (ro) 2009-01-30
SV1999000061A (es) 2000-03-14
AR020322A1 (es) 2002-05-08
HU226142B1 (en) 2008-05-28
CY1107533T1 (el) 2013-03-13
TNSN99090A1 (fr) 2005-11-10
DZ2788A1 (fr) 2003-12-01
NO20005762D0 (no) 2000-11-14
KR100607609B1 (ko) 2006-08-02
CN101319247A (zh) 2008-12-10
EP1076704A1 (en) 2001-02-21
NO20005762L (no) 2001-01-11
JP2002515247A (ja) 2002-05-28
HK1039963A1 (zh) 2002-05-17
CN101319247B (zh) 2012-12-12
CO5070701A1 (es) 2001-08-28
CZ302071B6 (cs) 2010-09-29
IL139136A0 (en) 2001-11-25
CN1309705A (zh) 2001-08-22
CU23272A1 (es) 2008-04-09
PT1076704E (pt) 2007-02-28
DE69934881D1 (de) 2007-03-08
BR9910504A (pt) 2001-01-09
PE20000475A1 (es) 2000-07-07
PL344407A1 (en) 2001-11-05
PA8472601A1 (es) 2000-09-29
HK1039963B (zh) 2008-09-05
ATE351907T1 (de) 2007-02-15
HUP0101948A2 (hu) 2001-09-28
SK17242000A3 (sk) 2001-07-10
IL139136A (en) 2009-05-04
SK288100B6 (sk) 2013-07-02
UA73719C2 (en) 2005-09-15
MY130274A (en) 2007-06-29
BRPI9910504B1 (pt) 2016-08-09
CN100366742C (zh) 2008-02-06
BG65139B1 (bg) 2007-03-30
TR200003354T2 (tr) 2001-03-21
DE69934881T2 (de) 2007-11-08
WO1999060128A1 (en) 1999-11-25
DK1076704T3 (da) 2007-03-12
NZ508098A (en) 2003-09-26
AU4078499A (en) 1999-12-06
PL201675B1 (pl) 2009-04-30

Similar Documents

Publication Publication Date Title
HN1999000075A (es) Agonistas y antagonistas il-2 selectivos
ES2194992T3 (es) Procedimientos para la incorporacion estable de sustancias en matrices vitreas secas esponjosas, y composiciones asi obtenidas.
GT199900102A (es) Fenoxipropanolaminas, procedimiento para su preparacìon y composiciones farmacèuticasque las contienen.
AR020442A1 (es) Agonistas de 5ht2serotonergicos para el tratamiento de glaucoma
GT199700015A (es) Inhibidores de metaloproteinasa, composiciones farmaceuticas que las contienen y su uso farmaceutico y metodosyeficazproducto intermedio para su preparacion.
MX9302944A (es) Compuestos en n-yodopropargil-hidantoina, sus composiciones y su preparacion y empleo como agentes antimicrobianos.
AR033717A1 (es) Composicion pesticida que comprende compuestos de malononitrilo
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
ES2153076T3 (es) Agentes herbicidas basados en bencisoxazol y bencisotiazol sustituidos.
MX9602806A (es) Derivados del 1,2,4-oxadiazol y su uso como parasiticidas para animales.
DK1257176T3 (da) Anvendelse af syrestabile proteaser i dyrefoder
ES2183407T3 (es) Composicion polimera de mecha para un producto de vela ambientadora.
ES2033235T3 (es) N-n' -diacilhidrazinas n'-sustituidas para insecticidas.
AR021596A1 (es) Compuestos que inhiben la procolageno c-proteinasa.
CO5221025A1 (es) 4-trifluorometil-3-oxazolilpiridinas, procedimiento para su preparacion, agentes que las contienen y su uso como agente para la lucha contra organismos daninos
CY1105009T1 (el) Συνθεση καχαλαλιδης f
ES2120762T3 (es) Nuevas composiciones herbicidas.
ES2184398T3 (es) Mezclas herbicidas a base de aclonifeno y de clomazona.
ES2153503T3 (es) Nuevas composiciones herbicidas sinergicas que comprenden compuestos de 4-benzoilisoxazoles y 2,6-dinitroanilinas.
ES2193297T3 (es) Agentes que previenen el mal olor humano.
ES2147453T3 (es) Antagonistas de adenosina, procedimiento para su preparacion y su uso como medicamentos.
AR030853A1 (es) Composicion plaguicida
BR9806193A (pt) Composição bi-aromáticos ligados por um radical heteroetinileno e composições farmacêuticas e cosméticas que os contêm
BR0112600A (pt) Compostos calcilìticos